Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Real-world treatment duration of ruxolitinib and use of transfusion among 2268 patients with myelofibrosis: An analysis of the Medicare fee-for-service claims database

View Full Paper
Ask AI
Bookmark
Share

Authors

TSTaylor SchwartzSASusan M. AdamsANAhmad Naim

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals ruxolitinib treatment duration and transfusion patterns in adults with myelofibrosis.

Key Points

  • The aim is to evaluate the real-world duration of ruxolitinib treatment and related transfusion use in patients with myelofibrosis.
  • Retrospective analysis of Medicare claims data from 2268 adults diagnosed with myelofibrosis.
  • Evaluation of treatment duration, transfusion rates, and anemia management using descriptive statistics and Kaplan-Meier method.
  • Identification of demographic and clinical characteristics of patients receiving ruxolitinib and transfusions.
  • Median ruxolitinib treatment duration was 37 months among myelofibrosis patients.
  • Approximately 30% of patients remained on ruxolitinib after the follow-up period.
  • Transfusion rates declined significantly, with nearly half of transfusion-requiring patients becoming transfusion-free within a year.

Cite This Study

Schwartz et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e5b1https://doi.org/10.1182/blood-2025-6391
View Full Paper
Ask AI
Bookmark
Share